Logo image of ASPI

ASP ISOTOPES INC (ASPI) Stock Fundamental Analysis

USA - NASDAQ:ASPI - US00218A1051 - Common Stock

13.885 USD
+0.56 (+4.24%)
Last: 10/14/2025, 12:30:09 PM
Fundamental Rating

3

Overall ASPI gets a fundamental rating of 3 out of 10. We evaluated ASPI against 83 industry peers in the Chemicals industry. While ASPI seems to be doing ok healthwise, there are quite some concerns on its profitability. ASPI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ASPI has reported negative net income.
ASPI had a negative operating cash flow in the past year.
ASPI Yearly Net Income VS EBIT VS OCF VS FCFASPI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

ASPI has a worse Return On Assets (-73.55%) than 95.18% of its industry peers.
ASPI's Return On Equity of -396.17% is on the low side compared to the rest of the industry. ASPI is outperformed by 92.77% of its industry peers.
Industry RankSector Rank
ROA -73.55%
ROE -396.17%
ROIC N/A
ROA(3y)-45.32%
ROA(5y)N/A
ROE(3y)-74.55%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ASPI Yearly ROA, ROE, ROICASPI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

ASPI's Gross Margin of 39.26% is amongst the best of the industry. ASPI outperforms 81.93% of its industry peers.
ASPI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASPI Yearly Profit, Operating, Gross MarginsASPI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

ASPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ASPI has more shares outstanding
The debt/assets ratio for ASPI is higher compared to a year ago.
ASPI Yearly Shares OutstandingASPI Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
ASPI Yearly Total Debt VS Total AssetsASPI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ASPI has an Altman-Z score of 5.27. This indicates that ASPI is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.27, ASPI belongs to the top of the industry, outperforming 95.18% of the companies in the same industry.
ASPI has a Debt/Equity ratio of 3.98. This is a high value indicating a heavy dependency on external financing.
ASPI has a worse Debt to Equity ratio (3.98) than 90.36% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.98
Debt/FCF N/A
Altman-Z 5.27
ROIC/WACCN/A
WACC8.62%
ASPI Yearly LT Debt VS Equity VS FCFASPI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

ASPI has a Current Ratio of 14.72. This indicates that ASPI is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 14.72, ASPI belongs to the best of the industry, outperforming 98.80% of the companies in the same industry.
A Quick Ratio of 14.56 indicates that ASPI has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 14.56, ASPI belongs to the top of the industry, outperforming 98.80% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.72
Quick Ratio 14.56
ASPI Yearly Current Assets VS Current LiabilitesASPI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for ASPI have decreased strongly by -122.01% in the last year.
The Revenue has grown by 99.57% in the past year. This is a very strong growth!
EPS 1Y (TTM)-122.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-331.25%
Revenue 1Y (TTM)99.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.22%

3.2 Future

ASPI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.06% yearly.
ASPI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 179.09% yearly.
EPS Next Y-121.05%
EPS Next 2Y35.08%
EPS Next 3Y-10.06%
EPS Next 5Y47.06%
Revenue Next Year260.98%
Revenue Next 2Y308.01%
Revenue Next 3Y198.08%
Revenue Next 5Y179.09%

3.3 Evolution

ASPI Yearly Revenue VS EstimatesASPI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
ASPI Yearly EPS VS EstimatesASPI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ASPI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ASPI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASPI Price Earnings VS Forward Price EarningsASPI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASPI Per share dataASPI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A cheap valuation may be justified as ASPI's earnings are expected to decrease with -10.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.08%
EPS Next 3Y-10.06%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ASPI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASP ISOTOPES INC

NASDAQ:ASPI (10/14/2025, 12:30:09 PM)

13.885

+0.56 (+4.24%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-17 2025-11-17
Inst Owners45.38%
Inst Owner Change1.97%
Ins Owners14.2%
Ins Owner Change14.01%
Market Cap1.28B
Analysts82.86
Price Target11.22 (-19.19%)
Short Float %23.41%
Short Ratio3.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-417.82%
Min EPS beat(2)-818%
Max EPS beat(2)-17.65%
EPS beat(4)0
Avg EPS beat(4)-226.99%
Min EPS beat(4)-818%
Max EPS beat(4)-17.65%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-21.75%
Min Revenue beat(2)-26.57%
Max Revenue beat(2)-16.92%
Revenue beat(4)0
Avg Revenue beat(4)-12.27%
Min Revenue beat(4)-26.57%
Max Revenue beat(4)-2.45%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)41.94%
EPS NQ rev (1m)-33.33%
EPS NQ rev (3m)-20%
EPS NY rev (1m)-223.08%
EPS NY rev (3m)-223.08%
Revenue NQ rev (1m)-50%
Revenue NQ rev (3m)-58.75%
Revenue NY rev (1m)-32.01%
Revenue NY rev (3m)-40.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 278.54
P/FCF N/A
P/OCF N/A
P/B 50.58
P/tB 58.35
EV/EBITDA N/A
EPS(TTM)-1.4
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.05
BVpS0.27
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.55%
ROE -396.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.26%
FCFM N/A
ROA(3y)-45.32%
ROA(5y)N/A
ROE(3y)-74.55%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 3.98
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1289.23%
Cap/Sales 253.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.72
Quick Ratio 14.56
Altman-Z 5.27
F-Score3
WACC8.62%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-122.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-331.25%
EPS Next Y-121.05%
EPS Next 2Y35.08%
EPS Next 3Y-10.06%
EPS Next 5Y47.06%
Revenue 1Y (TTM)99.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.22%
Revenue Next Year260.98%
Revenue Next 2Y308.01%
Revenue Next 3Y198.08%
Revenue Next 5Y179.09%
EBIT growth 1Y-55.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-316.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-361.77%
OCF growth 3YN/A
OCF growth 5YN/A